Aikium Inc.


Aikium is a biotechnology company focused on unlocking the undruggable proteome using AI-powered trillion-molecule screening. Their mission is to deliver groundbreaking therapies by combining advanced AI models, synthetic biology, and large-scale protein libraries. They aim to achieve rapid therapeutic breakthroughs and collaborate with leading pharma and academic institutions.

Industries

biopharma
life-science
machine-learning
therapeutics

Nr. of Employees

small (1-50)

Aikium Inc.

Berkeley, California, United States, North America


Products

AI-driven platform for ultra-large-scale protein screening and design

An integrated platform combining proteome-scale ML, generative protein language models, and a synthetic biology display system to design, express, and screen ultra-large protein libraries for binder discovery.


Services

Collaborative discovery partnerships

Collaborative projects with pharmaceutical and academic partners to apply ultra-large-scale AI-driven protein discovery workflows to partner targets.

AI-driven protein design and screening services

Provides AI-based sequence design, prioritization, and screening support using generative models and proteome-scale ML to generate and evaluate candidate proteins.

Expertise Areas

  • AI-driven protein discovery
  • Ultra-large library generation and screening
  • Generative protein sequence design
  • Synthetic biology for library construction
  • Show More (4)

Key Technologies

  • Ultra-large protein library display technologies
  • Proteome-scale deep learning
  • Generative protein language models
  • Synthetic biology for expression and display
  • Show More (2)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.